Pharmaceuticals: 2026-Q2 Sector Review

Macroeconomic Backdrop and Sectoral Context

Bangladesh's pharmaceuticals sector operates within a constrained macroeconomic environment that shapes both input costs and demand dynamics. GDP growth stands at 4.14 per cent per annum according to World Bank WDI data for FY2023, though the Bureau of Statistics reports a provisional figure of 6.0 for the same fiscal year. This discrepancy underscores measurement uncertainty that complicates sector-level planning. Annual average CPI inflation of 10.47 per cent, based on World Bank 2024 data, exerts upward pressure on production costs across labor, utilities, and imported intermediates. The Bangladesh Bureau of Statistics figure for December 2024 sits lower at 9.7 per cent, but either measure indicates sustained price pressure that compresses household spending capacity and elevates working capital requirements for manufacturers.

Foreign exchange reserves, measured at USD 31.07 billion under the IMF BPM6 method as of December 2024, remain sufficient but tight relative to historical levels. The exchange rate of 122.75 BDT per USD at end-December 2024 continues to define the cost ceiling for imported active pharmaceutical ingredients and excipients. The merchandise trade deficit, with exports at USD 44.5 billion and imports at USD 63.7 billion for FY2023-24, reflects a structural gap that places persistent downward pressure on the currency and, by extension, on pharmaceutical input costs. Remittance inflows of USD 23.91 billion in FY2023-24, growing 10.66 per cent year on year, provide a partial offset but do not eliminate the foreign exchange constraint that pharmaceutical firms face when sourcing imported raw materials.

The fiscal deficit of 4.7 per cent of GDP and public debt at 40.1 per cent of GDP, both for the 2023-24 fiscal cycle, delineate the boundaries of available public investment and subsidy space. The banking sector's non-performing loan ratio of 35.73 per cent under the Basel III reclassification published in late 2025 constrains credit channels that pharmaceutical companies rely upon for capacity expansion and working capital. This ratio, markedly elevated, signals that domestic financing conditions for the sector are likely to remain restrictive, reinforcing the importance of retained earnings, equity issuance, and strategic partnerships as funding sources.

Recent Sector Performance and Corporate Developments

The pharmaceuticals industry recorded export earnings of USD 194.63 million during the July to April period of FY26, representing a 9.7 per cent increase over the corresponding period in the prior fiscal year. This growth trajectory, while positive, must be interpreted against a modest base and within a global market that remains competitive for generic manufacturers from South Asia. The sector's export performance demonstrates resilience given the macroeconomic headwinds, but the absolute figure indicates substantial room for expansion before pharmaceuticals can serve as a meaningful foreign exchange earner comparable to ready-made garments.

Two leading firms anchor the sector's recent corporate activity. Beximco Pharmaceuticals saw trading of its Global Depositary Receipts resume on the London Stock Exchange's Alternative Investment Market on June 26 to 27, 2026. This resumption restores access to international capital market investors and reestablishes a price discovery mechanism outside the domestic exchange. The company's board approved a 47.5 per cent cash dividend for the year ending June 2025, with August 2, 2026 designated as the record date. A dividend at this level signals board confidence in near-term cash generation, though it also raises the question of whether retained earnings are being deployed optimally against the sector's capacity expansion requirements.

Square Pharmaceuticals, the other market leader, entered into a contract manufacturing agreement with C2C Pharma Ltd., with board approval granted on June 28, 2026. This agreement expands production capacity through a partnership structure rather than wholly owned greenfield investment, a approach that conserves capital while adding volume. Contract manufacturing also positions Square to capture incremental demand without committing to the full fixed cost burden of new facilities. The choice of capacity expansion via partnership reflects a pragmatic response to the constrained financing environment described above, where banking sector stress limits the availability and affordability of debt finance.

Structural Position of the Sector

Bangladesh's pharmaceuticals industry holds a structurally important position in the domestic economy. The sector supplies the overwhelming majority of local medicine demand, though the precise share cannot be quantified from the supplied ledger and is therefore not stated here. What can be established from the available facts is that the government recognizes structural vulnerabilities in the supply chain and is acting on them through fiscal policy. The implementation of zero-duty and zero-VAT status for 51 new raw materials used in active pharmaceutical ingredient production represents a deliberate effort to deepen backward integration. API manufacturing capacity is the critical determinant of long-term cost competitiveness and supply security for any pharmaceutical industry, and the duty waiver directly addresses the cost barrier that has historically discouraged domestic API investment.

Simultaneously, the government is extending concessions to 17 basic raw materials and nine ingredients used specifically in cancer medicine production. Oncology medicines represent a high-value, high-growth therapeutic segment where import dependence carries both economic and public health costs. By targeting fiscal incentives at this segment, the government signals recognition that specialized medicine production is the next frontier for sector development beyond the broad generics base.

These policy measures, taken together, indicate a coherent industrial logic: reduce input costs for API production to build upstream capacity, and lower barriers in high-value therapeutic segments to move the sector up the value chain. The effectiveness of these concessions will depend on implementation speed, the responsiveness of existing manufacturers, and the stability of the broader fiscal and exchange rate environment in which these firms operate.

Risk Assessment

The sector faces several interlocking risks that policymakers and industry participants must monitor. First, the exchange rate channel remains the dominant transmission mechanism for input cost volatility. With the currency at 122.75 BDT per USD and reserves at USD 31.07 billion, any further depreciation would immediately raise the cost of imported active pharmaceutical ingredients, excipients, and packaging materials. Firms with limited pricing power in the domestic market, where government price regulation applies to essential medicines, would absorb margin compression. The inability to pass through cost increases to consumers creates a structural vulnerability for manufacturers of price-controlled formulations.

Second, the banking sector's non-performing loan ratio of 35.73 per cent under the Basel III reclassification represents a systemic risk to corporate finance across all sectors, pharmaceuticals included. Even financially sound pharmaceutical companies face higher risk premiums, tighter covenants, and reduced credit availability when the banking system carries impaired assets of this magnitude. The sector's reliance on domestic bank financing for working capital and expansion makes this an acute vulnerability.

Third, inflation at 10.47 per cent (World Bank annual average for 2024) or 9.7 per cent (BBS, December 2024) erodes real household incomes and threatens demand volumes, particularly for non-essential and branded formulations. While essential medicine demand is relatively price-inelastic, the broader product portfolios of large pharmaceutical firms include categories where consumer demand is discretionary and sensitive to real income compression.

Fourth, export concentration risk applies to the sector's international earnings. The USD 194.63 million in exports during July to April of FY26 represents growth, but the geographic and product composition of these exports is not detailed in the available data. If exports are concentrated in a small number of destination markets or therapeutic categories, the growth trajectory remains vulnerable to regulatory actions, quality compliance challenges, or demand shifts in those specific markets.

Fifth, the resumption of Beximco Pharmaceuticals' GDR trading on the London Stock Exchange's Alternative Investment Market, while positive for market access, reintroduces exposure to international investor sentiment and price volatility on a foreign exchange. Adverse developments in GDR pricing could affect domestic market confidence and the company's ability to use the instrument for future capital raising.

Policy Levers and Strategic Options

The available policy levers fall into four broad categories, each with distinct time horizons and implementation requirements.

The first lever is fiscal, and it is already being deployed. The zero-duty and zero-VAT treatment of 51 API raw materials and the concessions on 17 basic raw materials and nine cancer medicine ingredients constitute the current fiscal intervention. The policy priority now shifts from design to execution: ensuring that customs procedures, bond facilities, and regulatory approvals do not create administrative friction that negates the intended cost reduction. The government should monitor utilization rates of these concessions and publish data on the volume of imports entering under the waived tariff lines. If uptake is slow, the binding constraint may lie in procedural bottlenecks rather than tariff levels, and administrative reform would then take priority over further fiscal concessions.

The second lever is exchange rate and foreign exchange management. The pharmaceuticals sector is structurally a net importer of inputs, which means that a stable and predictable exchange rate is more valuable to manufacturers than a nominally competitive currency that introduces cost volatility. Policy measures that stabilize reserve levels and reduce exchange rate volatility serve the sector's interests directly. The current reserve level of USD 31.07 billion provides a buffer, but the merchandise trade gap, with imports of USD 63.7 billion against exports of USD 44.5 billion, indicates that sustained reserve accumulation requires either export growth across all sectors or continued remittance strength. Remittances at USD 23.91 billion, growing 10.66 per cent year on year, remain essential to maintaining the external position that pharmaceutical firms depend upon for input procurement.

The third lever is financial sector reform. The non-performing loan ratio of 35.73 per cent under Basel III reclassification is not solely a banking sector issue; it is a cross-cutting constraint on industrial investment that affects pharmaceuticals as much as any other manufacturing subsector. Resolution of impaired assets, strengthened governance at state-owned and private banks, and restoration of credit transmission mechanisms would lower the cost and increase the availability of financing for pharmaceutical capacity expansion. This lever operates on a longer time horizon but addresses a structural bottleneck.

The fourth lever is regulatory and trade policy for export market access. The 9.7 per cent growth in pharmaceutical exports to USD 194.63 million during July to April of FY26 demonstrates that international demand exists. Policy interventions that accelerate drug registration in target markets, strengthen the national regulatory authority to meet international standards, and negotiate mutual recognition agreements with destination market regulators would amplify the impact of the fiscal concessions already in place. Quality compliance infrastructure, including laboratory capacity and inspection regimes, is a prerequisite for sustained export growth and cannot be substituted by fiscal incentives alone.

Forward Assessment

The pharmaceuticals sector enters the second half of 2026 with genuine momentum. The corporate developments at Beximco Pharmaceuticals and Square Pharmaceuticals, both occurring in the final week of June 2026, signal active strategic repositioning by the sector's largest firms. The fiscal concessions on API and oncology raw materials provide a supportive policy environment. Export growth, while modest in absolute terms, confirms international competitiveness.

The binding constraints are macroeconomic and financial rather than sector-specific. Inflation of 10.47 per cent, a non-performing loan ratio of 35.73 per cent, and a merchandise trade deficit that pressures the exchange rate collectively define the risk envelope within which the sector must operate. Policy levers exist to address each constraint, but the pharmaceuticals sector alone cannot resolve them. What sector-specific policy can do is ensure that the fiscal concessions are implemented efficiently, that regulatory infrastructure supports both domestic quality assurance and export market access, and that the administrative environment does not impose costs that offset the intended benefits of the duty and VAT waivers.

The next two quarters will reveal whether the capacity expansion at Square Pharmaceuticals through the C2C Pharma agreement and the restored international market access at Beximco Pharmaceuticals translate into accelerated export growth and improved domestic market depth. The record date of August 2, 2026 for Beximco's dividend and the implementation timeline for the API raw material concessions will serve as proximate indicators of whether the sector's positive trajectory is being sustained.